| Trial ID: | L0612 |
| Source ID: | ChiCTR-IPC-15006339
|
| Associated Drug: |
Exenatide
|
| Title: |
Observation of the effect and safety of exenatide on hepatic biomarkers in elderly patients with type 2 diabetes complicated nonalcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
type 2 diabetes complicated nonalcoholic fatty liver disease
|
| Interventions: |
Groop Exenatide:Exenatide was initiated at 5 mcg twice daily while stopping their pre-study oral hypoglycemic drugs or taking them at reduced dose, titrated to 10 mcg twice daily after one month;Groop Glargine:Glargine was started with 0.1IU/kg once-dail
|
| Outcome Measures: |
markers of hepatic function;the controlled attenuation parameter (CAP);glycosylated hemoglobin;fasting plasma glucose.;postprandial plasma glucose;blood lipid;
|
| Sponsor/Collaborators: |
Metabolic Disease Hospital of Tianjin Medical University
|
| Gender: |
All
|
| Age: |
nannan
|
| Phases: |
Post-market
|
| Enrollment: |
Groop Exenatide:50;Groop Glargine:50;
|
| Study Type: |
Interventional study
|
| Study Designs: |
Case-Control study
|
| Start Date: |
27/04/2015
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
18 April 2017
|
| Locations: |
China
|
| URL: |
http://www.chictr.org.cn/showproj.aspx?proj=10866
|
